A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma.

Source:http://linkedlifedata.com/resource/pubmed/id/19755389

Clin. Cancer Res. 2009 Oct 1 15 19 6225-31

Download in:

View as

Triples

General Info

PMID
19755389